Mr. Craig Milne reports

INNOVOTECH INC. RECEIVES US$402,926 FOLLOWING EXIT FROM ITS POSITION IN A CANADIAN PRIVATE COMPANY

Innovotech Inc. has received $402,926 (U.S.) (approximately $550,562 (Canadian)) following the sale of its 120,000 shares in a privately held Canadian company, effective July 1, 2025, with proceeds received July 7 at close of business. The shares were acquired in February, 2021, as the consequence of a $150,000 convertible debenture that Innovotech investor Lonsdale Capital Corp. assigned to Innovotech in exchange for 625,000 common shares in Innovotech at a deemed price of 24 cents each. A further $33,339 (U.S.) is held back for working capital adjustments and indemnity, and a portion of this may be realized over the subsequent 18 months.

"The proceeds provide capital to continue executing on our plans, investing in profitable revenue growth and developing high-value technologies. We congratulate the teams involved in the transaction for their milestone achievement and our supporters at Lonsdale for their visionary work in building healthy businesses like ours," said Craig Milne, Innovotech chief executive officer.

About Innovotech Inc.

Innovotech is a diversified Canadian technology company with business operations in a growing portfolio of specialized laboratory services, biotechnology businesses and proprietary intellectual property. Innovotech manages several subsidiary companies. Innovotech Labs Corp. is a contract research organization that owns and provides proprietary devices for anti-microbial testing in multiple applications and commercializes anti-microbial silver solutions. Keystone Labs Inc. is a DEL-accredited lab serving the Canadian pharmaceutical industry and industrial markets. Innovotech owns a 60-per-cent stake in NouLifeSciences Inc., a company holding intellectual property related to anti-oxidant molecules with potential applications in cosmetics and various medical conditions, including neuropathies.

We seek Safe Harbor.